X
[{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Refana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Aims to Make 1 Billion Doses of COVID-19 Vaccine Candidate in 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Successfully completes Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","amount":"$830.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Announces Successful Completion Of Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$251.1 million","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Panacea Biotec Limited
Filters
×
FILTER:
Company
Sponsor
Country
Therapeutic Area
Study Phase
Companies By Therapeutic Area
Details:
The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were among the top 5.
Lead Product(s):
Tacrolimus
Therapeutic Area: Dermatology
Product Name: Pangraf
Highest Development Status: Approved
Product Type: Small molecule
Recipient:
Mankind Pharma
Deal Size: $251.1 million
Upfront Cash: Undisclosed
Deal Type: Agreement
February 01, 2022
Details:
DengiAll, a single-dose live-attenuated tetravalent vaccine induced robust, balanced neutralizing antibody responses against all four Dengue virus serotypes. After single-dose, more than 80% of participants showed Tri-valent response and ~95% showed multivalent response.
Lead Product(s):
Tetravalent Recombinant Chimeric Dengue Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: DengiAll
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 30, 2021
Details:
Patient recruitment and dosing is ongoing in Nuvation Bio’s Phase 1/2 study of its lead investigational compound, NUV-422, a CDK2/4/6 inhibitor, in patients with high-grade gliomas, including glioblastoma multiforme (GBM).
Lead Product(s):
NUV-422
Therapeutic Area: Oncology
Product Name: NUV-422
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Recipient:
Nuvation Bio
Deal Size: $830.0 million
Upfront Cash: Undisclosed
Deal Type: Merger
February 10, 2021
Details:
DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research, development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies.
Lead Product(s):
Tetravalent recombinant chimeric Dengue vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: DengiAll
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 24, 2020
Details:
Panacea Biotec has set production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.
Lead Product(s):
Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 08, 2020
Details:
Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World.
Lead Product(s):
Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Refana
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
June 10, 2020